The Role of Lenvatinib in the Evolving HCC Landscape: Optimizing Treatment Strategies From Intermediate to Advanced HCC
Richard S. Finn, MD; and Amit G. Singal, MD, MS, discuss how systemic therapy plays a growing role in hepatocellular carcinoma (HCC) management, particularly in embolization-eligible and advanced stages. Combining systemic therapies with locoregional treatments like transarterial chemoembolization has shown potential in overcoming resistance mechanisms. Trials like LEAP-012 and EMERALD-1 support this approach, indicating enhanced efficacy. Tyrosine kinase inhibitor (TKI)+immune checkpoint inhibitor combinations offer advantages over TKI monotherapy, but challenges remain in clinical adoption. Lenvatinib, a key player in first-line treatment, shows promise across stages and may extend to second-line therapy.
EP. 1: Current Treatment Practices in Embolization-Eligible HCC
March 11th 2025Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), particularly for patients with progressive or extensive disease. In locally advanced cases, systemic therapies, including immunotherapy combinations and tyrosine kinase inhibitors (TKIs), are first-line options. Patients typically transition from transarterial chemoembolization (TACE) to systemic therapy upon progression, high tumor burden, or liver function decline.
Watch
EP. 2: When to Move Beyond TACE: The Expanding Role of Systemic Therapy in Intermediate-Stage HCC
March 11th 2025Panelists discuss how combining systemic therapy with locoregional treatments like transarterial chemoembolization (TACE) aims to enhance therapeutic efficacy by addressing its limitations, such as incomplete tumor necrosis and hypoxia-induced progression. Tyrosine kinase inhibitors (TKIs) like lenvatinib and immune checkpoint inhibitors (ICIs) counteract TACE-induced resistance by inhibiting angiogenesis and boosting immune response, improving overall tumor control.
Watch
